ABSTRACT
Thermo-optical properties of the nanodisc and metal hole array plasmonic perfect absorber (PPA) metasurfaces were designed and characterized at mid-infrared wavelengths. Both, radiation emitter and detector systems operating in various spectral domains are highly sought after for a diverse range of applications, one example being future sensor networks employed in the internet-of-things. Reciprocity of the absorbance and emittance is shown experimentally, i.e., the PPAs are demonstrated to follow Kirchhoff's law where the patterns exhibiting a strong optical absorption were found to be effective thermal emitters. Hence, the Kirchhoff's law is experimentally validated for the metasurfaces in the IR spectral domain where there is a lack of solutions for spectrally narrow-band emitters. The highest efficiency of radiation-to-heat and heat-to-radiation conversion was obtained for Au-Si-Au composite structures.
ABSTRACT
Eltrombopag, an orally-active small molecule thrombopoietin (TPO) receptor agonist, was used for the first time in 2008 to treat patients with chronic idiopathic thrombocytopenic purpura. Here, we investigated the pharmacological effect of a new orally-active small molecule TPO receptor agonist which may be effective in treating these patients. 50% effective concentration values for cell proliferation with AS1670542 or eltrombopag were 1.9 and 13nM, respectively, while those for megakaryocyte colony formation from human cord blood CD34(+) cells with AS1670542 or eltrombopag were 260 and 950nM, respectively. On Day 14 after the start of administration, AS1670542 significantly increased the number of human platelets in non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice with transplanted human hematopoietic stem cells at 0.3 (P<0.05); in contrast, while administration of eltrombopag also increased the numbers of these platelets at 30mg/kg/day (P=0.058), no statistical significance was noted in the increase. Here, we identified AS1670542, a novel orally-active TPO receptor agonist which mimics the biological activity of TPO and may demonstrate greater in vitro and in vivo pharmacologically efficacy than eltrombopag.